EA039880B1 - Способ получения оптически активного соединения - Google Patents

Способ получения оптически активного соединения Download PDF

Info

Publication number
EA039880B1
EA039880B1 EA201992709A EA201992709A EA039880B1 EA 039880 B1 EA039880 B1 EA 039880B1 EA 201992709 A EA201992709 A EA 201992709A EA 201992709 A EA201992709 A EA 201992709A EA 039880 B1 EA039880 B1 EA 039880B1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
acid
compound
salt
reaction
Prior art date
Application number
EA201992709A
Other languages
English (en)
Russian (ru)
Other versions
EA201992709A1 (ru
Inventor
Саюри Хирано
Ёсиюки Такеда
Кодзи Накамото
Мотоки Икеути
Масато Китаяма
Масатоси Ямада
Дзюн-ити Каваками
Original Assignee
Дот Терапьютикс-1, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дот Терапьютикс-1, Инк. filed Critical Дот Терапьютикс-1, Инк.
Publication of EA201992709A1 publication Critical patent/EA201992709A1/ru
Publication of EA039880B1 publication Critical patent/EA039880B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EA201992709A 2017-05-30 2018-05-29 Способ получения оптически активного соединения EA039880B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017106280 2017-05-30
PCT/IB2018/053822 WO2018220533A2 (ja) 2017-05-30 2018-05-29 光学活性化合物の製造法

Publications (2)

Publication Number Publication Date
EA201992709A1 EA201992709A1 (ru) 2020-04-23
EA039880B1 true EA039880B1 (ru) 2022-03-23

Family

ID=64454503

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992709A EA039880B1 (ru) 2017-05-30 2018-05-29 Способ получения оптически активного соединения

Country Status (12)

Country Link
US (2) US10988469B2 (https=)
EP (2) EP3632441B1 (https=)
JP (2) JP7102233B2 (https=)
KR (1) KR102754527B1 (https=)
CN (2) CN111032047B (https=)
AU (1) AU2018276192B2 (https=)
CA (1) CA3065683A1 (https=)
EA (1) EA039880B1 (https=)
ES (1) ES2986461T3 (https=)
IL (1) IL270983B (https=)
MX (1) MX391164B (https=)
WO (1) WO2018220533A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo
CN113557227A (zh) * 2019-03-27 2021-10-26 协和医药化工股份有限公司 前列腺素的制造方法
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN114685564B (zh) * 2020-12-27 2023-09-22 西北大学 新型亚磷酰胺配体及其合成方法和应用
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
WO2026028053A2 (en) 2024-07-27 2026-02-05 Assia Chemical Industries Ltd. Process for the preparation of tovorafenib
CN119241530B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的药物合成工艺
CN119241529B (zh) * 2024-09-20 2026-04-10 武汉九州钰民医药科技有限公司 一种Tovorafenib的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709500B2 (en) * 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
US9556177B2 (en) * 2007-06-29 2017-01-31 Millennium Pharmaceuticals, Inc. Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764842B2 (en) * 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
US7754889B2 (en) * 2004-03-29 2010-07-13 Takasago International Corporation Optically active transition metal-diamine compound and process for producing optically active alcohol with the same
TWI345568B (en) * 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
MX351657B (es) * 2012-03-14 2017-10-23 Merck Sharp & Dohme Sales de alcaloide de cinchona bis-cuaternarias como catalizadores de transferencia de fase asimétrica.
CN107880075A (zh) 2012-03-28 2018-04-06 武田药品工业株式会社 铑催化剂和制备胺化合物的方法
TWI602803B (zh) * 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2015178846A1 (en) * 2014-05-20 2015-11-26 Sp Process Development Ab Process for the preparation of chiral amines from prochiral ketones
JP6638363B2 (ja) 2015-12-11 2020-01-29 株式会社大林組 掘削装置および杭孔の拡径方法
CN105524111B (zh) * 2016-01-25 2017-10-27 西北农林科技大学 手性亚磷酰胺单齿配体及其合成方法与应用
MX391164B (es) 2017-05-30 2025-03-21 Dot Therapeutics 1 Inc Metodo para producir compuesto opticamente activo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709500B2 (en) * 2002-02-18 2010-05-04 Astrazeneca Ab Chemical compounds
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
US9556177B2 (en) * 2007-06-29 2017-01-31 Millennium Pharmaceuticals, Inc. Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors

Also Published As

Publication number Publication date
EP3632441A2 (en) 2020-04-08
JP7420865B2 (ja) 2024-01-23
MX391164B (es) 2025-03-21
IL270983B (en) 2022-03-01
US20210347769A1 (en) 2021-11-11
KR102754527B1 (ko) 2025-01-14
JP2018203733A (ja) 2018-12-27
EP4406609A3 (en) 2024-10-02
AU2018276192A1 (en) 2020-01-16
AU2018276192B2 (en) 2022-05-19
EP4406609A2 (en) 2024-07-31
US20200317659A1 (en) 2020-10-08
MX2019014256A (es) 2022-03-31
JP7102233B2 (ja) 2022-07-19
KR20200013707A (ko) 2020-02-07
CN117447464A (zh) 2024-01-26
EP3632441A4 (en) 2021-01-13
WO2018220533A3 (ja) 2019-02-28
ES2986461T3 (es) 2024-11-11
CN111032047A (zh) 2020-04-17
EA201992709A1 (ru) 2020-04-23
WO2018220533A2 (ja) 2018-12-06
CA3065683A1 (en) 2018-12-06
EP3632441C0 (en) 2024-07-17
CN111032047B (zh) 2023-10-27
BR112019025355A2 (pt) 2020-06-23
JP2022116043A (ja) 2022-08-09
US10988469B2 (en) 2021-04-27
US12129249B2 (en) 2024-10-29
EP3632441B1 (en) 2024-07-17
IL270983A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
JP7420865B2 (ja) 光学活性化合物の製造法
US11053188B2 (en) Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides
DK2411385T3 (en) PROCESS FOR THE PREPARATION OF propionic acid derivatives
JP2005516036A6 (ja) 非ラセミsyn−1−(4−ヒドロキシ−フェニル)−2−(4−ヒドロキシ−4−フェニル−ピペリジン−1−イル)−1−プロパノ−ル化合物の製造方法
US20180079741A1 (en) Process for producing heterocyclic compound
HK40114634A (en) Method for producing optically active compound
BR112019025355B1 (pt) Métodos para a produção de compostos oticamente ativos, composto e forma oticamente ativa
HK40022701A (en) Method for producing optically active compound
HK40022701B (en) Method for producing optically active compound
US9878981B2 (en) Method for producing heterocyclic compound